kalshi
Financials
What will the FDA's decision be on DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical in 2026?
a full approval or an accelerated approval
78%
implied YES probability
-6.0pp 24h
Price history
Last 8 days ·
High 72% ·
Low 62%
· 7d +6.2pp
Recent news mentioning this market
-
Sweden Is Set to Keep 2026 Rate Hike on Table: Decision Guide
Bloomberg Economics · 1h ago
-
Clarivate Director Cornick Buys 900,000 Shares for $1.7 Million. What Does This Tell Investors About the Outlook for 2026?
Motley Fool · 13h ago
Related stocks
Trade on Kalshi
Open on Kalshi
Frenzy Capital does not execute trades on prediction markets — we aggregate
public order-book and trading data for analysis.
Prediction market data reflects speculative event probabilities, not guaranteed outcomes. This is not investment advice. See Terms §17.